Assays for Hemato-Oncology

Acute Myeloid Leukemia (AML) is a biologically heterogeneous disease characterized by malignant growth within the hematopoietic system. Its incidence rises with age, involving the excessive proliferation of myeloid cells in the bone marrow, leading to compromised hematopoiesis. If left untreated, AML rapidly progresses and can become fatal within a short span. Therefore, a swift and accurate AML diagnosis is of utmost importance. AML is categorized based on WHO classification¹, considering cytomorphologic, cytogenetic, and molecular genetic features. In line with the 2022 European LeukemiaNet (ELN)² and WHO (2016)¹ guidelines, genetic anomalies such as gene fusions not only bear prognostic significance but are also essential for diagnostic categorization. This underscores the pivotal role of genetic insights in unraveling the intricate nature of AML.

1. Arber, D. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127, 2391-2405; https://doi.org/10.1182/blood-2016-03-643544 (2016)
2. Döhner, H. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140, 1345-1377; https://doi.org/10.1182/blood.2022016867 (2022)